{"entity":{"id":"nct03257033","kind":"trial","name":"Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC","aka":[],"tldr":"A phase 3 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by RenovoRx, now recruiting.","summary":"Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC is a phase 3 interventional study registered as NCT03257033 by RenovoRx, with 190 participants planned, started 2018-03-12 and due to reach its primary completion in 2027-06. Interventions recorded: Gemcitabine, nab-paclitaxel and RenovoCath.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03257033","url":"https://clinicaltrials.gov/study/NCT03257033"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03257033","phase":"3","setting":"Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer","sponsor":"RenovoRx","enrolled":190,"outcomes":[]},"route":"/trials/nct03257033/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}]}}